Physician profile
Robert E Briggs
NPI 1639131642
$3,223.57
in general payments reported to CMS, 2019-2025
23 companies · $748 in 2025
The $748 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $383 · 2020: $153 · 2021: $596 · 2022: $552 · 2023: $326 · 2024: $467 · 2025: $748.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,522 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,521.56 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $662.13 | 2019-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $632.19 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $344.59 | 2021-2024 | Ubrelvy, Vraylar |
| Novartis Pharmaceuticals Corporation | $260.03 | 2019-2025 | |
| Lilly USA, LLC | $210.31 | 2021-2025 | Zepbound, Mounjaro, Trulicity |
| Astrazeneca Pharmaceuticals Lp | $207.55 | 2020-2025 | Airsupra |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2025 | Cobenfy |
| Pfizer INC. | $114.50 | 2022-2025 | |
| Cardinal Health 200 LLC | $114.05 | 2019 | |
| Abbott Laboratories | $87.04 | 2022-2023 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $76.80 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $68.88 | 2019-2022 | |
| Esperion Therapeutics, INC. | $57.90 | 2020-2024 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.03 | 2021-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.89 | 2024-2025 | Xifaxan |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $30.00 | 2019-2022 | |
| Amarin Pharma, INC. | $29.79 | 2019-2020 | |
| Mylan Specialty L.P. | $23.65 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $17.73 | 2022 | |
| Exact Sciences Corporation | $16.36 | 2025 | Cologuard Collection Kit |
| Currax Pharmaceuticals LLC | $15.09 | 2024 | Onzetra Xsail, Contrave |
| Xeris Pharmaceuticals, INC. | $14.67 | 2021 | |
| Genentech USA, INC. | $14.39 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Briggs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.